	24/0=/20	24				
Dat	:e:24/07/20	Z1				
YOU	ır Name:Federica Fu	irtaro				
	Manuscript Title: Carcinomas in inflammatory bowel disease: an update on diagnostic imaging techniques					
ivia	nuscript number (if known)	):		-		
related to to the related The maximum The to the me	ated to the content of your ties whose interests may be transparency and does not extionship/activity/interest, a following questions apply nuscript only.  The author's relationships/act the epidemiology of hyperticular dication, even if that medication,	manuscript. "Related" mea e affected by the content of necessarily indicate a bias. it is preferable that you do to the author's relationshi ivities/interests should be ension, you should declare eation is not mentioned in the pport for the work reporte	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pert all relationships with manufacturers of antihypertens	tains sive		
				•		
		Name all entities with	Specifications/Comments			
		whom you have this	(e.g., if payments were made to you or to your			
		relationship or indicate none (add rows as	institution)			
		needed)				
		Time frame: Since the initial	Inlanning of the work			
1	All support for the present	None	-preming of the front			
1	manuscript (e.g., funding,	INOTIC				
	provision of study materials,					
	medical writing, article					
	processing charges, etc.)					
	No time limit for this item.			<u></u>		
		Time frame: past	36 months			
2	Grants or contracts from					
-	any entity (if not indicated					
	in item #1 above).	None				
	/					
3	Royalties or licenses					
	,					
		None				
4	Consulting fees	Janssen				

Payment or honoraria for

Janssen

	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	Janssen	
7	Support for attending meetings and/or travel	Janssen	
8	Patents planned, issued or pending	Janssen	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Janssen	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other services		
13	Other financial or non- financial interests	None	

FF has received consulting fees, payment or honoraria lectures, presentations, speakers bureaus, manuscript writing or educational events, payment for expert testimony, support for attending meetings and/or travel, patents planned, issued or pending, leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid from Janssen.

		10.11,12 3.00	2233112 1 311111
Da	te:24/07/20	21	
Yo	ur Name:Arianna Da	l Buono	
Ma	anuscript Title: Car	cinomas in inflammatory	bowel disease: an update on diagnostic imaging technique
Ma	anuscript number (if known)	):	
ln ·	the interest of transparency	we ask you to disclose a	II relationships/activities/interests listed below that are
		· ·	eans any relation with for-profit or not-for-profit third
	-	-	of the manuscript. Disclosure represents a commitment
-		_	. If you are in doubt about whether to list a
rel	ationship/activity/interest,	it is preferable that you d	o so.
		to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>
ma	nnuscript only.		
<b>T</b> !		inikiaa limkanaska aleeni 199	defined broadly. For everyla 15 commenced 15
			e defined broadly. For example, if your manuscript pertains
			e all relationships with manufacturers of antihypertensive
me	edication, even if that medic	ation is not mentioned in	tne manuscript.
	term Haller 1		additional transfer and the second
	· · · · · · · · · · · · · · · · · · ·	•	ed in this manuscript without time limit. For all other item
the	e time frame for disclosure i	s the past 36 months.	
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed) Time frame: Since the initia	al planning of the work
	All support for the present		ar planning of the work
	All support for the present manuscript (e.g., funding,	None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	t 36 months
<u> </u>	Grants or contracts from		
	any entity (if not indicated		
	in item #1 above).	None	
}	Royalties or licenses		
,	noyalties of licelises		
		None	

5

Payment or honoraria for

	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical writing, gifts or other services		
13	Other financial or non-	None	
	financial interests		

No conflicts of interest.		

V	e:24/07/	<sup>'</sup> 2021	
rour		Sicuso	
Man	nuscript Title:(	Carcinomas in inflammatory	bowel disease: an update on diagnostic imaging technique
Man	nuscript number (if knov	vn):	
relat parti to tra relat	ted to the content of you ies whose interests may ransparency and does no tionship/activity/interes	ur manuscript. "Related" mo be affected by the content ot necessarily indicate a bias st, it is preferable that you d	all relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a do so.  hips/activities/interests as they relate to the current
	ronowing questions app ruscript only.	ny to the author's relations	inpopactivities/initerests as they relate to the <u>current</u>
- 54.0	-		
med In ite	lication, even if that medem #1 below, report all	dication is not mentioned in	re all relationships with manufacturers of antihypertensive in the manuscript.  red in this manuscript without time limit. For all other item  Specifications/Comments (e.g., if payments were made to you or to your
		-	(e.g., it payments were made to you or to your institution)
		relationship or indicate	Institution)
		none ladd rows as	
		none (add rows as	
		needed)	
	All support for the present	needed) Time frame: Since the initi	
	All support for the present	needed) Time frame: Since the initi	
r	manuscript (e.g., funding,	needed) Time frame: Since the initi None	
r		needed) Time frame: Since the initi None	
r p r	manuscript (e.g., funding, provision of study material	needed) Time frame: Since the initi None	
r p r	manuscript (e.g., funding, provision of study material medical writing, article	needed) Time frame: Since the initi None	
r p r	manuscript (e.g., funding, provision of study material medical writing, article processing charges, etc.)	needed) Time frame: Since the initi None	ial planning of the work
r p r	manuscript (e.g., funding, provision of study material medical writing, article processing charges, etc.)	needed) Time frame: Since the initi None	ial planning of the work
r r r	manuscript (e.g., funding, provision of study material medical writing, article processing charges, etc.)	needed) Time frame: Since the initi None	ial planning of the work
r r r r	manuscript (e.g., funding, provision of study material medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated	needed) Time frame: Since the initi None	ial planning of the work
r r r r	manuscript (e.g., funding, provision of study material medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from	needed) Time frame: Since the initi None	ial planning of the work
r r r r	manuscript (e.g., funding, provision of study material medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	needed) Time frame: Since the initi  None  S,  Time frame: pas	ial planning of the work
r r r r	manuscript (e.g., funding, provision of study material medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated	needed) Time frame: Since the initi  None  S,  Time frame: pas	ial planning of the work
r r r r	manuscript (e.g., funding, provision of study material medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	needed) Time frame: Since the initi  None  Time frame: pas	ial planning of the work
r r r r r r r r r r r r r r r r r r r	manuscript (e.g., funding, provision of study material medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	needed) Time frame: Since the initi  None  S,  Time frame: pas	ial planning of the work

Payment or honoraria for

	lectures, presentations, speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other services		
13	Other financial or non-	None	
	financial interests		

No conflicts of	of interest.			

Da	te:24/	07/2021	
Υo	ur Name:Maria	angela Allocca	
			bowel disease: an update on diagnostic imaging techniques
Ma	anuscript number (if k	nown):	
rel pa to	ated to the content of rties whose interests i transparency and doe	your manuscript. "Related" mo may be affected by the content	all relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a do so.
	e following questions anuscript only.	apply to the author's relationsh	hips/activities/interests as they relate to the current
to	the epidemiology of h		e <u>defined broadly</u> . For example, if your manuscript pertains re all relationships with manufacturers of antihypertensive in the manuscript.
	· •	all support for the work report sure is the past 36 months.	ted in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)  Time frame: Since the initi	al planning of the work
	All support for the pres		di planning of the work
	manuscript (e.g., funding provision of study mate medical writing, article processing charges, etc.  No time limit for this it	erials,	
		Time frame: pas	st 36 months
	Grants or contracts from any entity (if not indication in item #1 above).		
	Royalties or licenses	Nikkiso Europe Janssen, Abbvie and Pfizer	
	Consulting fees	Nikkiso Europe Janssen, Abbvie and	

4

		Pfizer	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Nikkiso Europe, Janssen, Abbvie and Pfizer	
6	Payment for expert testimony	Nikkiso Europe, Janssen, Abbvie and Pfizer	
7	Support for attending meetings and/or travel	Nikkiso Europe, Janssen, Abbvie and Pfizer	
8	Patents planned, issued or pending	Nikkiso Europe, Janssen, Abbvie and Pfizer	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Nikkiso Europe, Janssen, Abbvie and Pfizer	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Nikkiso Europe, Janssen, Abbvie and Pfizer	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

MA received royalties or licenses, consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, payment for expert testimony, support for attending meetings and/or travel, patents planned, issued or pending, participation on a Data Safety Monitoring Board or Advisory Board, leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, from Nikkiso Europe, Janssen, Abbvie and Pfizer.

		10111112 2130	
Date	e:24/07/20	21	
	r Name:Ferdinando		bowel disease: an update on diagnostic imaging technique
		_	bowei disease: an update on diagnostic imaging technique
IVIAII	iuscript number (ii known	J·	
relat part to tr	ted to the content of your ies whose interests may b	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment is. If you are in doubt about whether to list a o so.
	following questions apply uscript only	to the author's relationsh	ips/activities/interests as they relate to the current
to th	•	ension, you should declare	e <u>defined broadly</u> . For example, if your manuscript pertain e all relationships with manufacturers of antihypertensive the manuscript.
	em #1 below, report all su time frame for disclosure i		ed in this manuscript without time limit. For all other iten
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	al planning of the work
	All support for the present	None	
	manuscript (e.g., funding,		
1 -	provision of study materials,		
	medical writing, article		
	processing charges, etc.)  No time limit for this item.		
		Time frame: pas	t 36 months
	Grants or contracts from		
	any entity (if not indicated		
	in item #1 above).	None	
3 1	Royalties or licenses		
		None	
. (	Consulting fees	None	

Payment or honoraria for

	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical writing, gifts or other services		
13	Other financial or non-	None	
	financial interests		

Please	place an	"X"	next to t	he fo	llowing	statement	to in	dicate	your a	greemen	ıt:
--------	----------	-----	-----------	-------	---------	-----------	-------	--------	--------	---------	-----

No conflicts of interest.		

\_X\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

		10.002 2.00	
Da	te:24/07/20	21	
Yo	ur Name:Alessandra	Zilli	
Ma	nuscript Title: Car	cinomas in inflammatory	bowel disease: an update on diagnostic imaging technique
Ma	nuscript number (if known)	:	
	-		Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third
pa	rties whose interests may be	e affected by the content	of the manuscript. Disclosure represents a commitment
	-	· ·	s. If you are in doubt about whether to list a
rel	ationship/activity/interest,	it is preferable that you d	lo so.
		to the author's relationsh	nips/activities/interests as they relate to the <u>current</u>
ma	nuscript only.		
Th	a author's relationshins (act	ivitias/intarasts should be	e <u>defined broadly</u> . For example, if your manuscript pertains
	•		e <u>defined broadiy</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive
	the epidemiology of hyperto edication, even if that medic		•
ш	dication, even if that medic	ation is not mentioned in	the manuscript.
	town #1 holow romant all acc	anaut fau tha wault nanaut	ad in this manuscript without time limit. For all other team
	· · · · · · · · · · · · · · · · · · ·	•	ed in this manuscript without time limit. For all other item
tne	e time frame for disclosure i	s the past 36 months.	
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initial	al planning of the work
	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
	time mine for tins item.	Time frame: pas	st 36 months
	Grants or contracts from		
	any entity (if not indicated		
	in item #1 above).	None	
}	Royalties or licenses		
		None	
4	Consulting fees	None	

5

Payment or honoraria for

	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-	None	
	financial interests		

No conflicts of interest.			

Ja	te:24/07/20	)21		
	ur Name:Gionata Fio			
Ma	anuscript Title: Car	rcinomas in inflammatory b	powel disease: an update on diagnostic imaging techniqu	ıes
	,	,		
rel pa to	ated to the content of your rties whose interests may b	manuscript. "Related" me e affected by the content o necessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.	
	e following questions apply anuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>	
to	• •	ension, you should declare	defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive the manuscript.	
	item #1 below, report all su e time frame for disclosure i	• •	d in this manuscript without time limit. For all other iter	ms,
		Name all entities with	Specifications/Comments	
		Name all entities with	Specifications/Comments (e.g., if payments were made to you or to your	
		whom you have this	(e.g., if payments were made to you or to your	
		whom you have this relationship or indicate	-	
		whom you have this relationship or indicate none (add rows as	(e.g., if payments were made to you or to your	
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)	
1	All support for the present	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)	
1	All support for the present	whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)	
1	manuscript (e.g., funding,	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)	
1	manuscript (e.g., funding, provision of study materials,	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)	
1	manuscript (e.g., funding, provision of study materials, medical writing, article	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)	
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)	
1	manuscript (e.g., funding, provision of study materials, medical writing, article	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)  planning of the work	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia  None	(e.g., if payments were made to you or to your institution)  planning of the work	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from	whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia  None	(e.g., if payments were made to you or to your institution)  planning of the work	
11	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia  None  Time frame: past	(e.g., if payments were made to you or to your institution)  planning of the work	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated	whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia  None	(e.g., if payments were made to you or to your institution)  planning of the work	
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia  None  Time frame: past	(e.g., if payments were made to you or to your institution)  planning of the work	
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated	whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia  None  Time frame: past	(e.g., if payments were made to you or to your institution)  planning of the work	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia  None  Time frame: past	(e.g., if payments were made to you or to your institution)  planning of the work	
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia  None  Time frame: past  None  MSD, Takeda	(e.g., if payments were made to you or to your institution)  planning of the work	
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia  None  Time frame: past  None  MSD, Takeda Pharmaceuticals,	(e.g., if payments were made to you or to your institution)  planning of the work	
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia  None  Time frame: past  None  MSD, Takeda	(e.g., if payments were made to you or to your institution)  planning of the work	

		C1 C	
		Sandoz, Samsung and	
		Janssen	
		Pharmaceuticals	
4	Consulting fees	MSD, Takeda	
		Pharmaceuticals,	
		AbbVie, Pfizer,	
		Celltrion, Amgen,	
		, ,	
		Sandoz, Samsung and	
		Janssen	
		Pharmaceuticals	
5	Payment or honoraria for	MSD, Takeda	
	lectures, presentations,	Pharmaceuticals,	
	speakers bureaus,	AbbVie, Pfizer,	
	manuscript writing or	Celltrion, Amgen,	
	educational events	Sandoz, Samsung and	
		Janssen	
		Pharmaceuticals	
6	Dayment for avecet		
١٥	Payment for expert testimony	MSD, Takeda	
	testimony	Pharmaceuticals,	
		AbbVie, Pfizer,	
		Celltrion, Amgen,	
		Sandoz, Samsung and	
		Janssen	
		Pharmaceuticals	
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	MSD, Takeda	
	Safety Monitoring Board or	Pharmaceuticals,	
	Advisory Board	AbbVie, Pfizer,	
		Celltrion, Amgen,	
		_ · · · · · · · · · · · · · · · · · · ·	
		Sandoz, Samsung and	
		Janssen	
		Pharmaceuticals	
10	Leadership or fiduciary role	MSD, Takeda	
	in other board, society,	Pharmaceuticals,	
	committee or advocacy	AbbVie, Pfizer,	
	group, paid or unpaid	Celltrion, Amgen,	
		Sandoz, Samsung and	
		Janssen	
		Jan 55011	

		Pharmaceuticals	
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

GF received royalties or licenses, consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, payment for expert testimony, participation on a Data Safety Monitoring Board or Advisory Board, leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, from MSD, Takeda Pharmaceuticals, AbbVie, Pfizer, Celltrion, Amgen, Sandoz, Samsung and Janssen Pharmaceuticals.

Date	:24/0	)7/2021	
Man	uscript Title:	_ Carcinomas in inflamr	matory bowel disease: an update on diagnostic imaging technique
Man	uscript number (if kn	own):	
relate partic to tra relate	ed to the content of es whose interests mansparency and does ionship/activity/inte	your manuscript. "Relat nay be affected by the co not necessarily indicate rest, it is preferable that	sclose all relationships/activities/interests listed below that are ted" means any relation with for-profit or not-for-profit third ontent of the manuscript. Disclosure represents a commitment e a bias. If you are in doubt about whether to list a it you do so.
<u>manı</u>	<u>uscript only</u> .		
medi In ite	ication, even if that r	nedication is not mentic	reported in this manuscript without time limit. For all other item
		Name all entities w	vith Specifications/Comments
		whom you have thi	· ·
		relationship or indi	
		none (add rows as	
		needed)	
		Time frame: Since t	the initial planning of the work
	All support for the prese		
	manuscript (e.g., fundin		
	provision of study mater	riais,	
	nedical writing, article processing charges, etc.	1	
	No time limit for this ite	•	
			me: past 36 months
: G	Grants or contracts from	n	
	nny entity (if not indicat		
	n item #1 above).	None	
R	Royalties or licenses		
	) III 6	None	
·   C	Consulting fees	None	

Payment or honoraria for

	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
	financial interests		

No conflicts of interest.		

Da	nte:24/07/20	21	
Υo	ur Name:Silvio Dane	se	
M	anuscript Title: Car	cinomas in inflammatory b	oowel disease: an update on diagnostic imaging techniques
re pa to	lated to the content of your irties whose interests may be	manuscript. "Related" me e affected by the content o necessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a o so.
	e following questions apply anuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to m	the epidemiology of hypertoedication, even if that medic	ension, you should declare ation is not mentioned in t pport for the work reporte	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.  d in this manuscript without time limit. For all other items
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as	(e.g., if payments were made to you or to your institution)
		needed)	Manning of the weath
	1	Time frame: Since the initia	planning of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 months
	Grants or contracts from		
	any entity (if not indicated	N	
	in item #1 above).	None	
	Royalties or licenses	Schering- Plough, AbbVie, MSD, UCB Pharma, Ferring,	

Pharmacosmos,

		Actelion, Alphawasserman, Genentech, Grunenthal, Pfizer, Astra Zeneca, Novo Nordisk, Cosmo Pharmaceuticals, Vifor and Johnson & Johnson, Nikkiso Europe GMBH, Theravance.	
4	Consulting fees	Schering- Plough, AbbVie, MSD, UCB Pharma, Ferring, Cellerix, Millenium Takeda, Nycomed, Pharmacosmos, Actelion, Alphawasserman, Genentech, Grunenthal, Pfizer, Astra Zeneca, Novo Nordisk, Cosmo Pharmaceuticals, Vifor and Johnson & Johnson, Nikkiso Europe GMBH, Theravance.	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Schering- Plough, AbbVie, MSD, UCB Pharma, Ferring, Cellerix, Millenium Takeda, Nycomed, Pharmacosmos, Actelion, Alphawasserman, Genentech, Grunenthal, Pfizer, Astra Zeneca, Novo Nordisk, Cosmo Pharmaceuticals, Vifor and Johnson & Johnson, Nikkiso Europe GMBH, Theravance.	

6	Payment for expert	Schering- Plough,	
	testimony	AbbVie, MSD, UCB	
		Pharma, Ferring,	
		Cellerix, Millenium	
		Takeda, Nycomed,	
		Pharmacosmos,	
		Actelion,	
		Alphawasserman,	
		Genentech,	
		Grunenthal, Pfizer,	
		Astra Zeneca, Novo	
		Nordisk, Cosmo	
		Pharmaceuticals,	
		Vifor and Johnson &	
		Johnson, Nikkiso	
		Europe GMBH,	
		Theravance	
7	Support for attending	Schering- Plough,	
	meetings and/or travel	AbbVie, MSD, UCB	
		Pharma, Ferring,	
		Cellerix, Millenium	
		Takeda, Nycomed,	
		Pharmacosmos,	
		Actelion,	
		Alphawasserman,	
		Genentech,	
		Grunenthal, Pfizer,	
		Astra Zeneca, Novo	
		Nordisk, Cosmo	
		Pharmaceuticals,	
		Vifor and Johnson &	
		Johnson, Nikkiso	
		Europe GMBH,	
		Theravance.	
8	Patents planned, issued or	Schering- Plough,	
	pending	AbbVie, MSD, UCB	
		Pharma, Ferring,	
		Cellerix, Millenium	
		Takeda, Nycomed,	
		Pharmacosmos,	
		Actelion,	
		Alphawasserman,	
		Genentech,	
		Grunenthal, Pfizer,	
		Astra Zeneca, Novo	
		Nordisk, Cosmo	

9	Participation on a Data Safety Monitoring Board or Advisory Board	Pharmaceuticals, Vifor and Johnson & Johnson, Nikkiso Europe GMBH, Theravance. M Allocca has served as consultant for Nikkiso Europe, Janssen, Abbvie and Pfizer Schering- Plough, AbbVie, MSD, UCB Pharma, Ferring, Cellerix, Millenium Takeda, Nycomed, Pharmacosmos, Actelion, Alphawasserman, Genentech, Grunenthal, Pfizer, Astra Zeneca, Novo Nordisk, Cosmo Pharmaceuticals, Vifor and Johnson & Johnson, Nikkiso	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options	Europe GMBH, Theravance. Schering- Plough, AbbVie, MSD, UCB Pharma, Ferring, Cellerix, Millenium Takeda, Nycomed, Pharmacosmos, Actelion, Alphawasserman, Genentech, Grunenthal, Pfizer, Astra Zeneca, Novo Nordisk, Cosmo Pharmaceuticals, Vifor and Johnson & Johnson, Nikkiso Europe GMBH, Theravance. None	

12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

SD received royalties or licenses, consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, payment for expert testimony, support for attending meetings and/or travel, patents planned, issued or pending, participation on a Data Safety Monitoring Board or Advisory Board, leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, from Schering- Plough, AbbVie, MSD, UCB Pharma, Ferring, Cellerix, Millenium Takeda, Nycomed, Pharmacosmos, Actelion, Alphawasserman, Genentech, Grunenthal, Pfizer, Astra Zeneca, Novo Nordisk, Cosmo Pharmaceuticals, Vifor and Johnson & Johnson, Nikkiso Europe GMBH, Theravance.